Treatment of Kidney Cancer: Priming the Immune Landscape in RCC with Vascular Normalizing Strategies
RCC Content Hub
Jodi K. Maranchie, MD, FACS, Associate Professor of Urology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, presents a review of how vascular normalization may help improve anti-tumor immunity in clear cell renal cell carcinoma.
She examines the CD8+ tumor infiltrating lymphocyte (TIL) paradox, the role of exhausted immune phenotypes, and the importance of tertiary lymphoid structures in the tumor microenvironment. Dr. Maranchie reviews how abnormal angiogenesis may impair immune recruitment and how vascular normalization may support the formation of high endothelial venules, tertiary lymphoid structures, and improved T-cell function.
She also reviews preclinical and translational work involving tumor blood vessel antigen vaccines, low-dose antiangiogenic therapy, and an ongoing pilot clinical study combining autologous dendritic cell vaccination with cabozantinib.
Dr. Maranchie provides insight into a novel immune-conditioning strategy that may help improve immunologic fitness and therapeutic response in renal cell carcinoma.
Don't forget to join the GRU Community: https://grandroundsinurology.com/register/
Follow us on Twitter/X: https://x.com/GRUrology
And like and subscribe to us here on YouTube!
#KidneyCancer #RCC #Immunotherapy #Urology